Carboxylesterases are essential enzymes
in the hydrolysis and detoxification of numerouspharmaceuticals and pesticides. They are vital
in mediat
ing organophosphate toxicity and
inactivat
ing many prodrugs such as
the chemo
therapeutic agent CPT-11. It is
therefore importantto study
the catalytic mechanism responsible for carboxylesterase-
induced hydrolysis, whichcan be accomplished through
the use of potent and selective
inhibitors. Trifluoromethyl ketone(TFK)-conta
ining compounds are
the most potent esterase
inhibitors described to date. The
inclusion of a thioe
ther moiety
to
the carbonyl fur
ther
increased TFK
inhibitor potency. Inthis study, we have syn
thesized
the sulfone analogues of a series of aliphatic and aromaticsubstituted thioe
ther TFKs to evaluate
their potency and solubility properties. This structuralchange shifted
the keto/hydrate equilibrium from <9% hydrate to >95% hydrate, form
ingalmost exclusively
the gem-diol. These new compounds were evaluated for
their
inhibition ofcarboxylesterase activity
in three different systems, rat liver microsomes, commercial porc
ineesterase, and juvenile hormone esterase
in cabbage
looper (
Trichoplusia ni) hemolymph. Themost potent
inhibitor of rat liver carboxylesterase activity was 1,1,1-trifluoro-3-(decane-1-sulfonyl)-propan-2,2-diol, which
inhibited 50% of
the enzyme activity (IC
50) at 6.3 ± 1.3 nMand was 18-fold more potent than its thioe
ther analogue. However,
the sulfone derivativeswere consistently poorer
inhibitors of porc
ine carboxylesterase activity and juvenile hormoneesterase activity, with IC
50 values rang
ing from low micromolar to millimolar. The compound1,1,1-trifluoro-3-(octane-1-sulfonyl)-propan-2,2-diol was shown to have a 10-fold greater watersolubility than its thioe
ther analogue, 1,1,1-trifluoro-3-octylsulfanyl-propan-2-one (OTFP). Thesenovel compounds provide fur
ther evidence of
the differences between esterase orthologs,suggest
ing that additional development of esterase
inhibitors may ultimately provide a
batteryof ortholog and/or isoform selective
inhibitors analogous to those available for o
ther complexenzyme families with overlapp
ing substrate specificity.